ArticleACS central science2018
Daylight-Mediated, Passive, and Sustained Release of the Glaucoma Drug Timolol from a Contact Lens.
Article in ACS central science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Light-Based Molecular Tools to Precisely Monitor and Operate β-Adrenoceptors.Medicinal research reviews · 2026Review
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- Recent Developments in the Optical Control of Adrenergic Signaling.Medicinal research reviews · 2025Review
- Article
- Fish Fin-Derived Non-Invasive Flexible Bioinspired Contact Lens for Continuous Ophthalmic Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Colloid-Forming Prodrug-Hydrogel Composite Prolongs Lower Intraocular Pressure in Rodent Eyes after Subconjunctival Injection.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- From Vision Correction to Drug Delivery: Unraveling the Potential of Therapeutic Contact Lens.Current drug delivery · 2025Review
- Chitosan nanoparticles laden contact lenses for enzyme-triggered controlled delivery of timolol maleate: A promising strategy for managing glaucoma.Drug delivery and translational research · 2024Article
- Vat photopolymerization printing of functionalized hydrogels on commercial contact lenses.Scientific reports · 2024Article
- Light-responsive biomaterials for ocular drug delivery.Drug delivery and translational research · 2023Review
- Caged-carvedilol as a new tool for visible-light photopharmacology of β-adrenoceptors in native tissues.iScience · 2022Article
- Review
- A Photoswitchable Ligand Targeting the βAngewandte Chemie (International ed. in English) · 2022Article
- Lab-on-a-Contact Lens: Recent Advances and Future Opportunities in Diagnostics and Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2022Review
- Inhibition of Neovascularization and Inflammation in a Mouse Model of Corneal Alkali Burns Using Cationic Liposomal Tacrolimus.Frontiers in bioengineering and biotechnology · 2021Article
- Therapeutic Ophthalmic Lenses: A Review.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timolol, a potent inhibitor of β-adrenergic receptors (βARs), is a first-line drug for decreasing the intraocular pressure (IOP) of patients with glaucoma. Timolol is administered using 0.5% eye-drop solutions at >3 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.